Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Letizia Foroni

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
Haematologica|April 21, 2009
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinibJamshid Sorouri Khorashad, Simon Wagner, Liat Greener, et al.
Blood|September 14, 2010
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapyAmr R Ibrahim, Christos Paliompeis, Marco Bua, et al.
British Journal of Haematology|August 1, 2020
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemiaGraeme Smith, Jane Apperley, Dragana Milojkovic, et al.
British Journal of Haematology|October 15, 2013
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemiaJacob Grinfeld, Gareth Gerrard, Mary Alikian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 5, 2011
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedureKatayoun Rezvani, Edward J Kanfer, David Marin, et al.
Blood|August 22, 2008
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poorDavid Marin, Dragana Milojkovic, Eduardo Olavarria, et al.
Blood|September 22, 2010
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitorsMustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, et al.
Blood|December 11, 2012
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemiaAthina Giannoudis, Lihui Wang, Andrea L Jorgensen, et al.
Haematologica|May 11, 2019
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitorsGeorgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsDavid Marin, Amr R Ibrahim, Claire Lucas, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Haematologica|April 21, 2009
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinibJamshid Sorouri Khorashad, Simon Wagner, Liat Greener, et al.
Blood|September 14, 2010
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapyAmr R Ibrahim, Christos Paliompeis, Marco Bua, et al.
British Journal of Haematology|August 1, 2020
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemiaGraeme Smith, Jane Apperley, Dragana Milojkovic, et al.
British Journal of Haematology|October 15, 2013
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemiaJacob Grinfeld, Gareth Gerrard, Mary Alikian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 5, 2011
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedureKatayoun Rezvani, Edward J Kanfer, David Marin, et al.
Blood|August 22, 2008
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poorDavid Marin, Dragana Milojkovic, Eduardo Olavarria, et al.
Blood|September 22, 2010
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitorsMustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, et al.
Blood|December 11, 2012
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemiaAthina Giannoudis, Lihui Wang, Andrea L Jorgensen, et al.
Haematologica|May 11, 2019
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitorsGeorgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsDavid Marin, Amr R Ibrahim, Claire Lucas, et al.
Pageof 9